The event emphasizes additional measures for obesity therapy.

Studies include Prime’s GLP-1 obesity research, the impact of social determinants of health and more.

Name Manufacturer Clinical Use Dosage Form Development Status FDA Decision adalimumab-bwwd 40 mg/0.4 mL (Hadlima™) (biosimilar to Abbvie’s Humira®) Organon RA; AS; PSO; PsA; JIA; CD; UC; HS;...

As demand for GLP-1a drugs for weight loss has increased, new data provides additional insights about this new class of medications.